




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Corrigendum

## Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242]

Ke Hu<sup>c</sup>, Wei-jie Guan<sup>b</sup>, Ying Bi<sup>d</sup>, Wei Zhang<sup>e</sup>, Lanjuan Li<sup>f</sup>, Boli Zhang<sup>g</sup>, Qingquan Liu<sup>h</sup>, Yuanlin Song<sup>i</sup>, Xingwang Li<sup>j</sup>, Zhongping Duan<sup>k</sup>, Qingshan Zheng<sup>l</sup>, Zifeng Yang<sup>b</sup>, Jingyi Liang<sup>b</sup>, Mingfeng Han<sup>m</sup>, Lianguo Ruan<sup>n</sup>, Chaomin Wu<sup>i</sup>, Yunting Zhang<sup>c</sup>, Zhen-hua Jia<sup>a,\*</sup>, Nan-shan Zhong<sup>b,\*\*</sup>

<sup>a</sup> Hebei Yiling Hospital, National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, Hebei province 050035, China

<sup>b</sup> State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong province, 510120, China

<sup>c</sup> Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Zhangzhidong Road No. 99, Wuhan 430060, Hubei province, China

<sup>d</sup> Department of Gynaecology and Obstetrics, Wuhan Red Cross Hospital, 392 Hongkong Road, Wuhan 430015, Hubei province, China

<sup>e</sup> Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China

<sup>f</sup> The First Affiliated Hospital of College of Medicine, Zhejiang province, China

<sup>g</sup> The First Teaching Hospital of Tianjin University of traditional Chinese medicine

<sup>h</sup> Beijing Hospital of traditional Chinese medicine, Beijing, China

<sup>i</sup> Zhongshan Hospital Affiliated Fudan University, Shanghai, China

<sup>j</sup> Beijing Ditan Hospital Capital Medical University, Beijing, China

<sup>k</sup> Youan Hospital Capital Medical University, Beijing, China

<sup>l</sup> Shanghai University of traditional Chinese medicine, Shanghai, China

<sup>m</sup> Fuyang Second People's Hospital, Fuyang, China

<sup>n</sup> Wuhan Jinyintan Hospital, Wuhan, Hubei province, China

## Corrigendum

1. Shijiazhuang Yiling Pharmaceutical Co., Ltd. provided part of the funding (accounting for 10.41%) and donated the study drugs (Lianhua Qingwen capsules, equivalent to CNY 29,600) for this research, but had no role in the data acquisition, statistical analysis and writing of this article.

2. The corresponding author, Dr. Zhen-hua Jia is the son-in-law of Yiling Wu, who is the founder of the study drug manufacturer, Shijiazhuang Yiling Pharmaceutical Co., Ltd.

3. Shijiazhuang Yiling Pharmaceutical Co., Ltd. and Hebei Yiling Hospital are two independent legal entities.

4. Shijiazhuang Yiling Pharmaceutical Co., Ltd. and Yiling Collateral Disease Company, as sibling companies both under the control of Yiling Pharmaceutical Technology Co., Ltd, are two completely independent legal entities.

5. This clinical trial was registered at the Chinese Clinical Trial Registry (<https://www.chictr.org.cn>) by Mr. Shuolong Han (applicant), an employee of Shijiazhuang Yiling Pharmaceutical Co., Ltd.

6. A total of 284 patients with Covid-19 were enrolled from 23 hospitals located in nine provinces throughout mainland China. No hospital enrolled more than 17% cases of the studied population. Also, no patient was enrolled at the Hebei Yiling Hospital, where the corresponding author, Dr Zhen-hua Jia, is working.

DOI of original article: <https://doi.org/10.1016/j.phymed.2020.153242>.

\* Corresponding author at: Hebei Yiling Hospital, National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, Hebei 050035, China

\*\* Corresponding author at: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, China.

E-mail addresses: [jzhjiazhenhua@163.com](mailto:jzhjiazhenhua@163.com) (Z.-h. Jia), [nanshan@vip.163.com](mailto:nanshan@vip.163.com) (N.-s. Zhong).

<https://doi.org/10.1016/j.phymed.2021.153800>



7. The corresponding author, Dr. Zhen-hua Jia, as the leader of Hebei Provincial Department of Science and Technology NCP Prevention and Control Emergency Scientific Research Project (Grant no. 20277708D), played the role in “funding acquisition” as to direct this government

funding for the study.

8. This research retained a third-party CRO company to monitor the data acquisition and to ensure the quality of data.

9. Other authors declare that they have no conflict of interest.